dm+d

Unassigned

New Medicines

Locally advanced, unresectable or metastatic bile duct cancer (cholangiocarcinoma) - first-line

Information

New molecular entity
NuCana
NuCana

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Developed using ProTide technology to overcome the limitations of nucleoside analogs which are mainly cancer resistance mechanisms that limit efficacy, it is comprised of gemcitabine and a phosphoramidate moiety. Given on days 1 and 8 of a 21-day cycle
Incidence is 1-2 per 100,000 population per year in the UK and the USA. Most cases occur in those aged over 60 years [1].
Locally advanced, unresectable or metastatic bile duct cancer (cholangiocarcinoma) - first-line
Intravenous infusion